What is the recommended dosing regimen for Ozempic (semaglutide)?

Ozempic Dosing

Start Ozempic at 0.25 mg subcutaneously once weekly for 4 weeks, then increase to 0.5 mg once weekly; if additional glycemic control is needed after at least 4 weeks, escalate to the maximum dose of 1 mg once weekly. 1

Detailed Dosing Algorithm

Initial Titration Schedule

The FDA-approved dosing regimen follows a structured escalation protocol 1:

• Weeks 1-4: 0.25 mg subcutaneously once weekly

  • This dose is for treatment initiation only and is not effective for glycemic control
  • Serves to minimize gastrointestinal side effects during initiation

• Week 5 onward: 0.5 mg once weekly

  • This is the first therapeutic dose for glycemic control
  • Many patients achieve adequate control at this dose

• Optional escalation: 1 mg once weekly

  • Only increase if additional glycemic control is needed after at least 4 weeks on 0.5 mg
  • This is the maximum recommended dose for type 2 diabetes 1

Administration Guidelines

Timing and technique 1:

• Administer once weekly on the same day each week
• Can be given at any time of day, with or without meals
• Inject subcutaneously into abdomen, thigh, or upper arm
• Rotate injection sites each week within the same body region

Missed dose protocol 1:

• If ≤5 days since missed dose: administer as soon as possible
• If >5 days since missed dose: skip and resume regular schedule
• Minimum 2 days (48 hours) must separate doses if changing administration day

Context-Specific Dosing

For Type 2 Diabetes with Cardiovascular Disease

Semaglutide is indicated to reduce major adverse cardiovascular events (cardiovascular death, non-fatal MI, or stroke) in adults with type 2 diabetes and established cardiovascular disease 2, 1. The same dosing schedule applies, with the goal of reaching at least 0.5 mg weekly for cardiovascular benefit 2.

For Diabetic Kidney Disease

No dose adjustment is required for renal impairment 3, 4. Semaglutide can be used safely across all stages of chronic kidney disease, including:

• eGFR ≥30 mL/min/1.73 m²: standard dosing
• eGFR 15-29 mL/min/1.73 m²: standard dosing (unlike exenatide or lixisenatide which require caution or are contraindicated)
• End-stage renal disease: limited data but no formal contraindication 5

This makes semaglutide particularly valuable for patients with diabetic kidney disease who need both glycemic control and cardiovascular protection 3.

Dose Escalation to Minimize Side Effects

The gradual titration is critical for tolerability 6. Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are dose-dependent and occur in approximately 40% of patients for nausea and 16% for vomiting 6. The 4-week intervals between dose increases allow:

• Development of tolerance to GI effects
• Assessment of glycemic response before further escalation
• Identification of patients who achieve goals at submaximal doses

Clinical judgment for individual titration 6:

• Some patients achieve strong response at 0.5 mg and can remain on this dose long-term
• If 2 consecutive doses missed: resume at same dose if previously well-tolerated, otherwise consider lowering
• If ≥3 consecutive doses missed: restart titration schedule from 0.25 mg

Important Safety Considerations

Contraindications 1

Absolute contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to semaglutide

Cautions and Monitoring 2, 6

Hypoglycemia risk: When combined with insulin or sulfonylureas, dose reduction of these agents may be necessary 6. Semaglutide alone carries very low hypoglycemia risk due to glucose-dependent insulin secretion.

Pancreatitis: Discontinue if suspected and do not restart if confirmed 2, 5. Consider alternative therapies in patients with history of pancreatitis 1.

Thyroid monitoring: Counsel patients about symptoms of thyroid tumors (neck mass, dysphagia, dyspnea, persistent hoarseness). Routine calcitonin monitoring is of uncertain value 1.

Drug interactions 6:

• Do not use with other GLP-1 receptor agonists or DPP-4 inhibitors
• May delay gastric emptying and affect absorption of oral medications requiring rapid onset
• When used with insulin, administer as separate injections (never mix), though can inject in same body region

Common Pitfalls to Avoid

1. Starting at therapeutic dose: The 0.25 mg starting dose is mandatory for tolerability—do not skip this step
2. Premature dose escalation: Wait the full 4 weeks at each dose level before increasing
3. Inadequate patient counseling: Patients must understand that initial GI side effects are common but typically transient
4. Forgetting renal advantage: Unlike some other GLP-1 RAs, semaglutide requires no dose adjustment for kidney disease
5. Mixing with insulin: Always administer as separate injections

Comparison with Higher-Dose Formulations

Note that the dosing described above is for Ozempic (approved for type 2 diabetes, maximum 1 mg weekly). A separate formulation exists for obesity management (Wegovy) that escalates to 2.4 mg weekly 7, 6. The titration schedule for the obesity indication follows a similar pattern but continues beyond 1 mg to reach 1.7 mg and ultimately 2.4 mg 6.